ACCESS Newswire

Novus Acquisition and Development, Corp.

Share
Novus Signs Partnership With PRAM, a Leading Pharmacy Consulting, and Underwriting Firm

Proud to be Aligned with a Proprietary Prescription Drug Benefits Powerhouse As We Begin Our Roll Out To Their Distribution Base

MIAMI, FL / ACCESSWIRE / July 19, 2021 / Novus Acquisition and Development, Corp. (OTC PINK:NDEV), through its wholly-owned subsidiary WCIG Insurance Services, LLC., is a hybrid health insurance entity and, the nation's first carrier offering cannabis health plans to recreational and medicinal users, is pleased to announce that it has finalized its partnership deal with PRAM to distribute, facilitate, and market the cannabis benefits package across the country.

PRAM, based in Brea, CA, is a leading pharmacy consulting and underwriting firm. The two companies working together will play a key role in the future of applying cannabis to American health plans as the United States approaches full federal legalization.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

Novus is proud to have come to terms with PRAM and its 32+ years of experience as a proprietary prescription Drug Benefits Consulting and Managing General Underwriter company that provides pharmacy cost containment in the marketplace. Their primary focus is:

  • Employer Groups: PRAM's client base of organizations that focus on pairing PRAM's pharmacy benefit programs alongside medical and ancillary products include distribution partners, consultants, brokers, agents, and insurance carriers across the country.
  • Insurance Carriers + Pharmacy Benefit Managers (PBMs): PRAM designs cost savings pharmacy programs by coordinating insurance carriers and PBMs in an effort to help clients manage pharmacy risk. As a fundamental process, PRAM's focus is to create, underwrite, manage, and market prescription drug insurance programs. These plans are advantageously paired with limited medical, short-term medical, and GAP plans. The most beneficial element to these plans is that they are guaranteed issue and ready to take to market. PRAM has many other custom product offerings in the pharmacy space aimed at saving money and creating healthier populations.
  • Plan Design Choices: PRAM intends to customize the Novus cannabis offering by tailoring formularies, copays, deductibles, specialty drug coverage, and specific drug inclusions or exclusions to best benefit the member experience.

Lisa Collier, CEO of PRAM, states: "Such innovation is at the core of PRAM's growth strategies and benefit design goals, so we are thrilled to be a part of a program that screams forward-thinking. National legalization is coming, and we'd rather be leading the dispensary network discount initiative than lagging behind it."

Frank Labrozzi, CEO of Novus, states: "It is of critical importance in business to foresee coming events. Our mission is to have the right alliance in preparation for that change. PRAM will provide that company partnership necessary for opening doors that once were challenges."

Alignment Competitive Advantages:

With the PRAM alliance, Novus is positioned to play a greater role in the future in the following areas:

  • More doctors will recommend medical cannabis as participation in reducing opiate prescriptions.
  • Take the stigma out of cannabis in the workplace with precedence set in the New Jersey Supreme Court, that ruled, under the New Jersey Law Against Discrimination ("LAD"), employees who legally use cannabis as permitted by the state's Compassionate Use of Cannabis of Medical Marijuana Act[i] may not be fired.
  • Ending prohibitions we could see a dramatic increase in our Provider Network where the big box and boutique retailers will likely sell pre-packaged cannabis in smokable and edible forms.

As Washington has to make up for a $6 Trillion dispersal of money in the past 18 months, there has never been a more critical time to legalize cannabis. More importantly, by ending prohibition of cannabis we will see med and rec users encouragingly help support our economy as they choose to have cannabis as a part of health insurance benefits.

Research Novus Now:

About PRAM

PRAM Insurance Services, Inc. was founded in 1989 by David P. Wilson. Dave has been in the insurance industry for over 40 years, and he has focused exclusively on prescription drug benefits since the beginning of PRAM when he identified a unique need for pharmacy cost containment in the marketplace.

For additional information on PRAM, please visit https://pram.com.

About Novus

Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as health, property & casualty, life, accident, and fixed annuities.

Novus' medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is completed the transaction is solely between the state-licensed dispensary and the registered patient.

The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly.

Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis-related products, we may be harmed by a change in enforcement by federal or state governments.

Forward-Looking Statements

This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Membership and providers may change, become inactive, or nonpaying from time to time. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact Information
855-228-7355
Email: info@getnovusnow.com

SOURCE: Novus Acquisition and Development Corporation



View source version on accesswire.com:
https://www.accesswire.com/655983/Novus-Signs-Partnership-With-PRAM-a-Leading-Pharmacy-Consulting-and-Underwriting-Firm

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Innodata to Report Third Quarter 2025 Results16.10.2025 14:30:00 CEST | Press release

NEW YORK, NY, AL / ACCESS Newswire / October 16, 2025 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Third Quarter 2025 results after the market closes on Thursday, November 6, 2025. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 42719 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available for seven days following the conference call, and Webcast replay will be available for 30 days following the c

Karbon-X Corp. Reports Q1 2026 Revenue Growth and Strengthened Financial Position16.10.2025 14:00:00 CEST | Press release

Revenue reached $35.7 million, marking a 27,883% year-over-year increase driven by accelerated trading activity, and the continued expansion of Karbon-X's global carbon operations. CALGARY, AB / ACCESS Newswire / October 16, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or "the Company"), a vertically integrated climate solutions company, today announced financial results for the first quarter ended August 31, 2025, marking record revenue growth and continued execution of its strategic plan. The full filing is available under the Company's profile on OTC Markets at www.otcmarkets.com/stock/KARX/overview Karbon-X's Q1 2026 results underscore its accelerating growth trajectory and strong execution across all areas of its business. Q1 2026 Highlights Revenue Growth Karbon-X delivered transformational top-line growth as its carbon trading operations scaled globally. Revenue reached $35.7 million, up 27,883% year-over-year compared to $127,429 in Q1 2025. Growth was driven by the successfu

RelyEZ Unveils VentureEdge 800: Next-Generation 800 V AC Energy Storage System Tailored for Europe16.10.2025 08:20:00 CEST | Press release

BRUSSELS, BE / ACCESS Newswire / October 16, 2025 / RelyEZ Energy Storage proudly announces the launch of its latest innovation, VentureEdge 800, a next-generation 800 V AC battery energy storage system (BESS) designed to meet Europe's evolving grid requirements. The launch coincides with RelyEZ's participation as a Gold Sponsor at the Energy Storage Global Conference (ESGC 2025) in Brussels, underscoring its commitment to supporting the region's clean energy transition with cutting-edge, bankable storage technologies. A New Standard for European Grid Compatibility Across Europe, most PV and wind installations operate on 0.8 kV/15 kV transformer infrastructure, while conventional 0.4 kV PCS systems require additional step-up transformers - increasing cost, space, and energy loss. VentureEdge 800 eliminates this layer entirely, offering direct 800 V AC connectivity for seamless integration with existing assets. This forward-looking design translates into: 5-15 % CAPEX savings through re

Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models16.10.2025 07:00:00 CEST | Press release

Enterprise platform, queried through natural language, to help pharma, biotech, and investors make better decisions. High-quality biological patient data, enriched and integrated for use by AI agents. PARIS, FRANCE, GB / ACCESS Newswire / October 16, 2025 / Owkin today announces the launch of K Pro, its co-pilot bringing advanced agentic AI to biomedical research and drug development. K Pro helps pharmaceutical companies and biotechs make smarter decisions across the discovery and development pipeline, increase clinical success rates, and deliver decision-grade, data-driven biological insights fast enough to change program trajectories.Owkin K Pro Owkin K Pro - the Agentic AI Co-Pilot for Biopharma Built on a decade of Owkin's AI innovation and in close collaboration with leading academic and industry partners, K Pro is a scientist-first co-pilot, accessible to both researchers and executives. Through natural language interaction, users can ask complex biological questions and receive

Compliance Couture: How SMX and CETI are Changing the Rules for Fashion Sustainability (NASDAQ: SMX)15.10.2025 19:10:00 CEST | Press release

NEW YORK, NY, NY / ACCESS Newswire / October 15, 2025 / Global fashion brands require a single, essential ingredient to thrive: trust. Trust that its product is genuine, trust that the craftsmanship is authentic, and trust that the values behind the brand align with the ones it promotes. From Paris ateliers to fast-fashion retailers, every label's reputation depends on that same promise of quality, consistency, and credibility. But the world has changed. Supply chains have gone global. Sustainability has become a shareholder demand. And the old way of proving trust - through reputation alone - no longer cuts it. Today, trust must be earned through evidence. That's where SMX (NASDAQ:SMX) and CETI, the European Center for Innovative Textiles, come in. Together, they've created something fashion has needed for years: proof. Their industrial-scale collaboration embeds molecular-level traceability directly into textile fibers, giving every material its own unbreakable digital fingerprint. I

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye